Overview

This trial has been completed.

Condition severe spasticity
Treatment gablofen® 3 mg/ml (baclofen injection)
Phase phase 3
Sponsor Mallinckrodt
Start date December 2012
End date August 2016
Trial size 153 participants
Trial identifier NCT01520545, CNS-GAB101US

Summary

Safety study to assess the 3 mg/mL baclofen injection (intrathecal) using a programmable pump

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
3 mg/mL Gablofen (baclofen Injection)
gablofen® 3 mg/ml (baclofen injection) baclofen injection
This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.

Primary Outcomes

Measure
The rate of inflammatory granulomas in patients given 3 mg/mL Gablofen® (baclofen injection) 3mg/mL by the intrathecal route of administration.
time frame: 36-months

Secondary Outcomes

Measure
Overall safety of 3 mg/mL Gablofen® (baclofen injection) given by the intrathecal route of administration
time frame: 36-months

Eligibility Criteria

Male or female participants at least 4 years old.

Inclusion Criteria: - 4 years of age or older - Subjects must be clinically diagnosed with sever spasticity and be receiving intrathecal baclofen - Subjects must have a SynchroMed® II Pump already implanted - Current treatment with intrathecal baclofen should be at the 2 mg/mL concentration - Life expectancy greater than or equal to 12 months - Signed written informed consent - Ability and willingness to comply with the study protocol for the duration of the study and with follow-up procedures Exclusion Criteria: - History or presence of malignancy, with the exception of adequately treated localized skin cancer (basal cell or squamous cell carcinoma) or carcinoma in-situ of the cervix, which is allowed - History of any allergic reaction to baclofen - History of inflammatory granulomas with an intrathecal infusion pump - Any previous history of neuroleptic malignant syndrome or malignant hyperthermia - As a result of medical review and physical examination, the Investigator considers the subject unfit for the study

Additional Information

Official title Study to Assess the Safety of 3 mg/mL Gablofen® (Baclofen Injection) Delivered by Intrathecal Administration Using the Synchromed® II Programmable Infusion System
Principal investigator Gerard Francisco, MD
Description This is a prospective 36-month Phase IIIb/IV clinical safety trial that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. All patients will be entered after signing an IRB approved informed consent. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated. Patients will be evaluated for clinical complications associated with the use of intrathecal baclofen that are considered signs and symptoms of an inflammatory granuloma, specifically new radicular pain at the level of the catheter tip, and/or spinal cord compression. An MRI scan with and without infusion will be performed (with consent of the patient) to evaluate the potential presence of an inflammatory granuloma if clinical signs exist. Events that may be related to an inflammatory granuloma will be classified as a definite granuloma, possible granuloma, other catheter related problem (confirmed not caused by a granuloma), or other clinical sequelae caused by the underlying disease or other infusion system related event.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Mallinckrodt.